Imbalanced Innovation: The High Cost of Europe's "Free Ride"
Executive Summary
By keeping pharmaceutical prices and utilization artificially low, Europe is losing more economically than it gains, says consulting group Bain & Co. Here's why-and what the drug industry should do about it